skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer

Abstract

Here in this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen (PSMA) avidity, stability and in vivo characteristics, as a PET imaging agent for prostate cancer (PCa), was prepared and evaluated. p-Fluorobenzoyl-aminohexanoate and 2-(3-hydroxypropyl)glycine were introduced into the PSMA-targeting scaffold yielding phosphoramidate 5. X-ray crystallography was performed on the PSMA/5 complex. [18F]5 was synthesized, and cell uptake and internalization studies were conducted in PSMA(+) LNCaP and CWR22Rv1 cells and PSMA(-) PC-3 cells. In vivo PET imaging and biodistribution studies were performed at 1 and 4 h post injection in mice bearing CWR22Rv1 tumor, with or without blocking agent. The crystallographic data showed interaction of the p-fluorobenzoyl group with an arene-binding cleft on the PSMA surface. In vitro studies revealed elevated uptake of [18F]5 in PSMA(+) cells (2.2% in CWR22Rv1 and 12.1% in LNCaP) compared to PSMA(-) cells (0.08%) at 4 h. In vivo tumor uptake of 2.33% ID/g and tumor-to-blood ratio of 265:1 was observed at 4 h. In conclusion, we have successfully synthesized, radiolabeled and evaluated a new PSMA-targeted PET agent. The crystal structure of the PSMA/5 complex highlighted the interactions within the arene-binding cleft contributing to the overall complex stability. The high target uptake andmore » rapid non-target clearance exhibited by [18F]5 in PSMA(+) xenografts substantiates its potential use for PET imaging of PCa.« less

Authors:
 [1];  [2];  [1];  [2];  [2];  [2];  [2];  [2];  [3];  [2];  [2];  [4]
  1. Washington State Univ., Pullman, WA (United States). Dept. of Chemistry
  2. Univ. of California, San Francisco, CA (United States). Dept. of Radiology and Biomedical Imaging
  3. Inst. of Biotechnology, Prague (Czech Republic)
  4. Washington State Univ., Pullman, WA (United States). Dept. of Chemistry; Cancer Targeted Technology, Woodinville, WA (United States)
Publication Date:
Research Org.:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
USDOE Office of Science (SC), Basic Energy Sciences (BES)
OSTI Identifier:
1214298
Alternate Identifier(s):
OSTI ID: 1252095
Grant/Contract Number:  
W-31-109-Eng-38; R01 CA140617; W81XWH-11-1-0464; 301/12/1513; CZ.1.05/1.1.00/02.0109
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Nuclear Medicine and Biology
Additional Journal Information:
Journal Volume: 42; Journal Issue: 10; Journal ID: ISSN 0969-8051
Publisher:
Elsevier
Country of Publication:
United States
Language:
ENGLISH
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; 59 BASIC BIOLOGICAL SCIENCES; Flourine-18; PET; PSMA; Phosphoramidate

Citation Formats

Ganguly, Tanushree, Dannoon, Shorouk, Hopkins, Mark R., Murphy, Stephanie, Cahaya, Hendry, Blecha, Joseph E., Jivan, Salma, Drake, Christopher R., Barinka, Cyril, Jones, Ella F., VanBrocklin, Henry F., and Berkman, Clifford E. A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. United States: N. p., 2015. Web. doi:10.1016/j.nucmedbio.2015.06.003.
Ganguly, Tanushree, Dannoon, Shorouk, Hopkins, Mark R., Murphy, Stephanie, Cahaya, Hendry, Blecha, Joseph E., Jivan, Salma, Drake, Christopher R., Barinka, Cyril, Jones, Ella F., VanBrocklin, Henry F., & Berkman, Clifford E. A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. United States. https://doi.org/10.1016/j.nucmedbio.2015.06.003
Ganguly, Tanushree, Dannoon, Shorouk, Hopkins, Mark R., Murphy, Stephanie, Cahaya, Hendry, Blecha, Joseph E., Jivan, Salma, Drake, Christopher R., Barinka, Cyril, Jones, Ella F., VanBrocklin, Henry F., and Berkman, Clifford E. 2015. "A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer". United States. https://doi.org/10.1016/j.nucmedbio.2015.06.003. https://www.osti.gov/servlets/purl/1214298.
@article{osti_1214298,
title = {A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer},
author = {Ganguly, Tanushree and Dannoon, Shorouk and Hopkins, Mark R. and Murphy, Stephanie and Cahaya, Hendry and Blecha, Joseph E. and Jivan, Salma and Drake, Christopher R. and Barinka, Cyril and Jones, Ella F. and VanBrocklin, Henry F. and Berkman, Clifford E.},
abstractNote = {Here in this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen (PSMA) avidity, stability and in vivo characteristics, as a PET imaging agent for prostate cancer (PCa), was prepared and evaluated. p-Fluorobenzoyl-aminohexanoate and 2-(3-hydroxypropyl)glycine were introduced into the PSMA-targeting scaffold yielding phosphoramidate 5. X-ray crystallography was performed on the PSMA/5 complex. [18F]5 was synthesized, and cell uptake and internalization studies were conducted in PSMA(+) LNCaP and CWR22Rv1 cells and PSMA(-) PC-3 cells. In vivo PET imaging and biodistribution studies were performed at 1 and 4 h post injection in mice bearing CWR22Rv1 tumor, with or without blocking agent. The crystallographic data showed interaction of the p-fluorobenzoyl group with an arene-binding cleft on the PSMA surface. In vitro studies revealed elevated uptake of [18F]5 in PSMA(+) cells (2.2% in CWR22Rv1 and 12.1% in LNCaP) compared to PSMA(-) cells (0.08%) at 4 h. In vivo tumor uptake of 2.33% ID/g and tumor-to-blood ratio of 265:1 was observed at 4 h. In conclusion, we have successfully synthesized, radiolabeled and evaluated a new PSMA-targeted PET agent. The crystal structure of the PSMA/5 complex highlighted the interactions within the arene-binding cleft contributing to the overall complex stability. The high target uptake and rapid non-target clearance exhibited by [18F]5 in PSMA(+) xenografts substantiates its potential use for PET imaging of PCa.},
doi = {10.1016/j.nucmedbio.2015.06.003},
url = {https://www.osti.gov/biblio/1214298}, journal = {Nuclear Medicine and Biology},
issn = {0969-8051},
number = 10,
volume = 42,
place = {United States},
year = {Tue Jun 09 00:00:00 EDT 2015},
month = {Tue Jun 09 00:00:00 EDT 2015}
}

Journal Article:

Citation Metrics:
Cited by: 42 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

11C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)
journal, April 2002


A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent: A Phosphoramidate PSMA-Targeted SPECT Agent
journal, October 2011


Anti-tumor effects of toxins targeted to the prostate specific membrane antigen
journal, August 2002


Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
journal, February 2009


Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen
journal, December 2003


89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
journal, July 2010


N -[ N -[( S )-1,3-Dicarboxypropyl]Carbamoyl]-4-[ 18 F]Fluorobenzyl-l-Cysteine, [ 18 F]DCFBC: A New Imaging Probe for Prostate Cancer
journal, May 2008


Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)
journal, July 2008


68 Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer
journal, July 2010


Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen
journal, January 2008


PSMA-targeted SPECT agents: Mode of binding effect on in vitro performance
journal, August 2012


Evaluation of i-STAT portable clinical analyzer in a neonatal and pediatric intensive care unit
journal, July 1997


Pseudoirreversible Inhibition of Prostate-Specific Membrane Antigen by Phosphoramidate Peptidomimetics
journal, December 2008


The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen
journal, December 2007


Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption
journal, October 2010


Reaction Mechanism of Glutamate Carboxypeptidase II Revealed by Mutagenesis, X-ray Crystallography, and Computational Methods
journal, May 2009


REFMAC 5 for the refinement of macromolecular crystal structures
journal, March 2011


PRODRG : a tool for high-throughput crystallography of protein–ligand complexes
journal, July 2004


Development of Inhibitor-Directed Enzyme Prodrug Therapy (IDEPT) for Prostate Cancer
journal, September 2014


Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates
journal, September 2004


Substrate specificity of prostate-specific membrane antigen
journal, November 2007


Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II
journal, July 2007


Structural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate Analogs
journal, March 2008


A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules
journal, September 2010


Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
journal, October 2012


Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human
journal, June 2006


Works referencing / citing this record:

PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer
journal, March 2017


Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
journal, March 2019


Fluorine-18 labelled building blocks for PET tracer synthesis
journal, January 2017